Summit Therapeutics Says Ivonescimab Plus Chemotherapy Cuts Death Risk 25% in Phase III Biliary Tract Cancer Trial

• Summit Therapeutics announced ivonescimab with chemotherapy improved overall survival versus durvalumab with chemotherapy in first-line advanced biliary tract cancer.
• Results from partner Akeso’s China-based Phase III HARMONi-GI1 trial are being presented today at the ESMO 2026 Congress in Madrid.
• The regimen also delayed disease progression, with a manageable safety profile and no additional safety signals.
• A US registration-enabling Phase II/III trial with ECOG-ACRIN is expected to begin site activation in the fourth quarter of 2026.
• Ivonescimab remains investigational in the United States and Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610251152BIZWIRE_USPR_____20261025_BW603151) on October 25, 2026, and is solely responsible for the information contained therein.